TRADITIONAL RISK FACTORS AND IL10 IN INFLAMMATION AND ATHEROSCLEROSIS DEVELOPMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
DOI:
https://doi.org/10.11603/1811-2471.2019.v.i4.10814Keywords:
psoriatic arthritis, psoriasis, cardiovascular diseases, dyslipidemia, atherosclerosis, C-reactive protein, uric acid, IL10Abstract
It is known that patients with psoriasis have increased risk of cardiovascular diseases (CVD) and cardiovascular death but the relationship of those events with influence of traditional risk factors (RF), inflammatory process and atherosclerosis development is not clear.
The aim – to study the role of RF, inflammation, level of IL10 in development of atherosclerosis in patients with psoriatic arthritis (PsA).
Material and Methods. The study included 42 patients with PsA who did not have atherosclerotic CVD, diabetes, chronic kidney disease and other serious diseases, did not take statins; the comparing group consisted of 20 patients with skin psoriasis (PS); and 20 practically healthy individuals who had no signs of rheumatic, infectious and other inflammatory diseases.
Results. It was found that in patients with PsA, the severity of the atherosclerotic process was more prominent compared to patients with PS and control group (the RF profiles were the same). The highest levels of C-reactive protein, fibrinogen, IL10, uric acid, intima-media complex thickness (IMT), atherosclerotic plaques frequency were found in patients in the PsA group, which may indicate a pathogenetic association of additional RF with the development of a more common atherosclerotic process.
Conclusions. In the development of atherosclerotic process in patients with PsA, in addition to the traditional risk factors, an important role is played by immune-inflammatory factors (CRP, IL10) and additional risk factors (CK).
References
Badokin, V.V., Badokin, Yu.V., & Korsakova, L. (2006). Terapevticheskaya aktivnost i bezopasnost artrofoona pri psoriaticheskom artrite [Therapeutic activity and safety of an arthropoon in psoriatic arthritis]. Consilium Medicum. 8. Retrieved from: http://con-med.ru/magazines/consilium_medicum/ 212569/212305 [in Russian].
Mastroianni, A., Minutilli, E., Mussi, A., Bordignon, V., Trento, E., D'Agosto, G., ..., & Berardesca, E. (2005). Cytokine profiles during infliximab monotherapy in psoriatic arthritis. British Journal of Dermatology, 153 (3), 531-536.
Gottlieb, A.B., Chao, C., & Dann, F. (2008). Psoriasis comorbidities. Journal of Dermatological Treatment, 19 (1), 5-21. DOI: https://doi.org/10.1080/09546630701364768
Milosavljevic, J., Lindqvist, U., & Elvin, A. (2005). Ultrasound and Power Doppler Evaluation of the Hand and Wrist in Patients with Psoriatic Arthritis. Acta Radiologica, 46 (4), 374-385. DOI: https://doi.org/10.1080/02841850510021256
Gottlieb, A., Korman, N.J., Gordon, K.B., Feldman, S.R., Lebwohl, M., Koo, J.Y., …, & Menter, A. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. Journal of the American Academy of Dermatology, 58 (5), 851-864. DOI: https://doi.org/10.1016/j.jaad.2008.02.040
Ellis, C.N., Mordin, M.M., & Adler, E.Y. (2003). Effects of alefacept on health-related quality of life in patients with psoriasis results from a randomized, placebo-controlled phase II trial. American Journal of Clinical Dermatology, 4 (2), 131-139. DOI: https://doi.org/10.2165/00128071-200304020-00005
Stefano, I., Eugenio, R., & Antonio, R. (2000). Echographic test and cyclosporin therapy in psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology, 14 (3), 232-233. DOI: https://doi.org/10.1046/j.1468-3083.2000.00061-9.x
Kochergin, N.G., Kochergin, S.N., & Smirnova, L.M. (2006). Itogi raboty Pervoy vsemirnoy konferentsii po psoriazu i psoriaticheskomu artritu meditsinskiy zhurnal [Results of the First World Conference on Psoriasis and Psoriatic Arthritis]. Retrieved from: http://www.rmj.ru/articles_4306.htm [in Russian].
Cohen, A.D., Dreiher, J., Shapiro, Y., Vidavsky, L., Vardy, D.A., Davidovici, B., Meyerovitch, J. (2008). Psoriasis and diabetes: a population-based cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 22 (5), 585-589. DOI: https://doi.org/10.1111/j.1468-3083.2008.02636.x
Titov, V.N., Boytsov, S.A., Urazalina, S.Zh., Sergiyenko, I.V., Andreyenko, Ye.Yu., Kukharchuk, V.V., & Karpov, Yu.A. (2013). Vzaimosvyaz mochevoy kisloty s pokazatelyamy lipidnogo obmena u lits s nizkim i srednim riskom po shkale SCORE. Ateroskleroz i dislipidemiya – Atherosclerosis and Dyslipidemia, 2, 31-39 [in Russian].
Chandran, V., Schentag, C.T., & Gladman, D.D. (2008). Sensitivity and specificity of the caspar criteria for psoriatic arthritis in a family medicine clinic setting. The Journal of Rheumatology, 35 (10), 2069-2070.
Mitchenko, O.I., & Lutay, M.I. (2011). Dislipidemiya: diagnostika, profilaktika i lecheniye: metod. rek. asotsiatsiy kardiologov Ukrainy [Dyslipidemia: diagnosis, prevention and treatment: methodological recommendations of Associations of Cardiologists of Ukraine]. Kyiv: Morion, 2011.
Kovalenko, V.M., Khimion, L.V., Lysenko, H.I., & Harmish, O.O. (2011). Vplyv imunnoho statusu ta lipidnykh faktoriv na prohresuvannia subklinichnoho aterosklerozu ta rozvytok sertsevo-sudynnykh zakhvoriuvan u patsiientiv iz revmatoidnym artrytom [Influence of immune status and lipid factors on the progression of subclinical atherosclerosis and the development of cardiovascular disease in patients with rheumatoid arthritis]. Ukr. revmatol. Zhurn. – The Ukrainian Journal of Rheumatology, 44 (2), 23-31 [in Ukrainian].
Gonzalez-Juanatey, C., Llorca, J., Amigo-Diaz, E., Dierssen, T., Martin, J., & Gonzalez-Gay, M.A. (2007). High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum., 57 (6), 1074-1080. DOI: https://doi.org/10.1002/art.22884
Franse, L.V., Pahor, M., Di Bari, M., Shorr, R.I., Wan, J.Y., Somes, G.W., & Applegate, W.B. (2000). Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J. Hypertens., 18, 1149-1154. DOI: https://doi.org/10.1097/00004872-200018080-00021
Grayson, P.C., Kim, S.Y., LaValley, M., & Choi, H. (2011). Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken), 63 (1), 102-110. DOI: https://doi.org/10.1002/acr.20344
Keenan, T., Blaha, M.J., Nasir, K., Silverman, M.G., Tota-Maharaj, R., Carvalho, J.A., Conceição, R.D., …, & Santos, R.D. (2012). Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am. J. Cardiol., 110 (12), 1787-1792. DOI: https://doi.org/10.1016/j.amjcard.2012.08.012
Lakoski, S.G., Yongmei Liu, M.S., Bridget Brosnihan, K. & Herrington, D.M. (2008). Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis, 197 (1), 443-447. DOI: https://doi.org/10.1016/j.atherosclerosis.2007.06.033
Caligiuri, G., Rudling, M., Ollivier, V., Jacob, M.P., Michel, J.B., Hansson, G.K., Nicoletti, A., et al. (2003). Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Molecular Medicine, 9, 10-17. DOI: https://doi.org/10.1007/BF03402102
Mälarstig, A., Eriksson, P., Hamsten, A., Lindahl, B., Wallentin, L., & Siegbahn, A. (2008). Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart, 94, 724-729. DOI: https://doi.org/10.1136/hrt.2007.119271
Heeschen, C., Dimmeler, S., Hamm, C.W., Fichtlscherer, S., Boersma, E., Simoons, M.L., Zeiher A.M., et al. (2003). Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Heart, 107, 2109-2114.
Mease, P., & Goffe, B.S. (2005). Diagnosis and treatment of psoriatic arthritis. J. Am. Acad. Dermatol., 52 (9), 1-19. DOI: https://doi.org/10.1016/j.jaad.2004.06.013
Mastroianni, A., Minutilli, E., Mussi, A., Bordignon, V., Trento, E., D'Agosto, G., Cordiali-Fei, P., & Berardesca, E. (2005). Cytokine profiles during infliximab monotherapy in psoriatic arthritis. British Journal of Dermatology, 153 (16), 531-536. DOI: https://doi.org/10.1111/j.1365-2133.2005.06648.x
